loading
Ensysce Biosciences Inc stock is traded at $2.24, with a volume of 98,791. It is up +1.82% in the last 24 hours and up +2.75% over the past month. Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$2.20
Open:
$2.2
24h Volume:
98,791
Relative Volume:
0.06
Market Cap:
$5.31M
Revenue:
-
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.7442
EPS:
-3.01
Net Cash Flow:
$-9.78M
1W Performance:
+5.16%
1M Performance:
+2.75%
6M Performance:
-70.45%
1Y Performance:
-63.84%
1-Day Range:
Value
$2.1766
$2.36
1-Week Range:
Value
$2.10
$2.36
52-Week Range:
Value
$1.62
$14.67

Ensysce Biosciences Inc Stock (ENSC) Company Profile

Name
Name
Ensysce Biosciences Inc
Name
Phone
(858) 263-4196
Name
Address
7946 IVANHOE AVENUE, LA JOLLA
Name
Employee
8
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ENSC's Discussions on Twitter

Compare ENSC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ENSC
Ensysce Biosciences Inc
2.24 5.22M 0 -11.28M -9.78M -3.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Ensysce Biosciences Inc Stock (ENSC) Latest News

pulisher
09:16 AM

Has Ensysce Biosciences Inc. Stock Ever Crashed Historical Volatility ReviewTop Performing Stocks - Newser

09:16 AM
pulisher
09:01 AM

Why is Ensysce Biosciences Inc. stock attracting strong analyst attentionAccess exclusive market insights for free - jammulinksnews.com

09:01 AM
pulisher
07:51 AM

Why Ensysce Biosciences Inc. stock attracts strong analyst attentionFree Top Growth Stock Recommendations - Newser

07:51 AM
pulisher
07:37 AM

How volatile is Ensysce Biosciences Inc. stock compared to the marketStay ahead with advanced stock screening tools - jammulinksnews.com

07:37 AM
pulisher
Jul 25, 2025

Is Ensysce Biosciences Inc. a good long term investmentHigh-yield investments - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Ensysce Biosciences Inc. stock priceExponential wealth increase - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Published on: 2025-07-25 08:23:29 - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Ensysce Biosciences Inc. stockHigh-performance investment picks - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

When (ENSC) Moves Investors should Listen - news.stocktradersdaily.com

Jul 22, 2025
pulisher
Jul 22, 2025

Ensysce Biosciences Inc. Stock Analysis and ForecastUnprecedented profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 16, 2025

Ensysce Biosciences initiates Phase 3 study of PF614 - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

FDA-Reviewed Phase 3 Trial Begins: Revolutionary Opioid Promises Pain Relief Without Abuse Risk - Stock Titan

Jul 16, 2025
pulisher
Jul 16, 2025

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614A Next-Generation OpioidDesigned to Deliver Powerful Pain Relief and Reduce Abuse - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Ensysce Biosciences Inc. stock price move sharplySolid Return Trade Selections - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Ensysce Biosciences Inc. stock performs during market volatilityHigh Yield Stock Selection - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

NAVY(boat pilot token) Tokenomics ExplainedHigh Return Potential - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Where are the Opportunities in (ENSC) - news.stocktradersdaily.com

Jul 12, 2025
pulisher
Jul 08, 2025

Travere Therapeutics (NASDAQ:TVTX) and Ensysce Biosciences (NASDAQ:ENSC) Head to Head Comparison - Defense World

Jul 08, 2025
pulisher
Jun 24, 2025

FDA-Designated Breakthrough Pain Drug Advances: New Solution to Opioid Overdose Crisis Shows Promise - Stock Titan

Jun 24, 2025
pulisher
Jun 21, 2025

(ENSC) Investment Analysis - news.stocktradersdaily.com

Jun 21, 2025
pulisher
Jun 15, 2025

Short Interest in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Declines By 71.5% - Defense World

Jun 15, 2025
pulisher
Jun 11, 2025

Leading Pain Experts Reveal New Opioid Abuse Prevention Technology at World's Largest Pain Conference - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

(ENSC) On The My Stocks Page - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 07, 2025

Ensysce Biosciences (NASDAQ:ENSC) Trading 1.7% Higher – Here’s What Happened - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

ensysce biosciences appoints baker tilly as new auditor By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

ensysce biosciences appoints baker tilly as new auditor - Investing.com

Jun 05, 2025
pulisher
Jun 04, 2025

Ensysce Flat on Receiving Grant - Baystreet.ca

Jun 04, 2025
pulisher
Jun 04, 2025

Ensysce Biosciences secures additional $5.3M NIDA grant - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Ensysce Biosciences secures additional $5.3M NIDA grant By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Ensysce Biosciences (ENSC) Secures $5.3M Grant to Advance Opioid Development | ENSC Stock News - GuruFocus

Jun 04, 2025

Ensysce Biosciences Inc Stock (ENSC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):